GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY

GRANEXIN 作为减轻皮肤辐射损伤的局部治疗药物

• 批准号: 10589744
• 负责人: GUATAM CHATNEKAR
• 金额: $ 265.71万
• 依托单位: XEQUEL BIO, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-03-16 至 2023-03-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10589744
• 关键词: Anti-Inflammatory Agents; Cutaneous; Development; Gel; Peptides; Property; Radiation Dose Unit; Radiation Injuries; Research; Safety; Skin wound healing; Therapeutic; Topical application; Validation; animal rule; efficacy study; efficacy validation; medical countermeasure; porcine model; safety study

Radiation Injury Description: Granexin® gel is an easy-to-use, stable, topically applied gel containing the short regulatory peptide (aCT1) that possesses potent anti-inflammatory properties and accelerates cutaneous wound healing. FirstString Research proposes to further validate the efficacy, safety, and therapeutic potential of Granexin in the mitigation and treatment of CRI. The proposed development efforts will support NDA submission to the FDA for Granexin as a medical countermeasure (MCM) for CRI under the Animal Rule.

描述：Granexin®凝胶是一种易于使用，稳定，局部应用的凝胶，含有短调节肽（aCT1），具有有效的抗炎特性，加速皮肤伤口愈合。FirstString Research拟进一步验证Granexin缓解和治疗CRI的疗效、安全性和治疗潜力。拟议的开发工作将支持Granexin作为CRI的医学对策（MCM）向FDA提交NDA。